Is tesofensine worth trying instead of (or alongside) a GLP-1?
Different mechanism, different feel. Tesofensine is a triple monoamine reuptake inhibitor with Astrup 2008 Phase 3 data of ~11% weight loss at 1 mg over 24 weeks. Feels closer to a low-dose stimulant than a GLP-1. Approved as Tesomet in Mexico, not in US/UK/EU. Stacking with GLP-1 is community practice, not validated.
Last reviewed · Panya.health editorial
What tesofensine actually is
Tesofensine (NS2330) is a triple monoamine reuptake inhibitor developed originally for Alzheimer's and Parkinson's, where it underperformed primary endpoints. The weight-loss effect was a side-finding that NeuroSearch then pursued through Phase 3. Astrup 2008 in The Lancet showed tesofensine produced 6.7%, 11.3%, and 12.8% weight loss at 0.25, 0.5, and 1 mg/day respectively over 24 weeks in obese adults, all on top of diet + exercise. Saniona / Medix licensed it in Latin America under the brand Tesomet (combined with metoprolol to manage cardiovascular side effects); it's available by prescription in Mexico and a handful of other markets. Not approved in the US, UK, EU, or most of Asia.
How it compares to a GLP-1
Mechanism: GLP-1 / GIP agonists reduce appetite by amplifying satiety signals to the hypothalamus and slowing gastric emptying. Tesofensine raises synaptic norepinephrine + dopamine + serotonin centrally, which suppresses appetite via a different pathway and produces a mild stimulant feel. Side-effect signature is therefore different: GLP-1 users report nausea, constipation, occasional dehydration; tesofensine users report dry mouth, insomnia, anxiety, increased heart rate, and elevated blood pressure (the metoprolol in Tesomet exists specifically to blunt the cardiovascular side). For someone who doesn't tolerate stimulants well or has any cardiovascular history, tesofensine is the wrong family. For someone who plateaus on tirzepatide and wants a non-overlapping mechanism to add, it's the most-discussed adjacent compound.
Stacking with GLP-1 is community practice, not validated
There is no published trial of tesofensine + GLP-1 combination in humans. The community framing 'tesofensine for the recomp / appetite-during-the-day, GLP-1 for the satiety-floor' is theoretical. Both compounds elevate cardiovascular load in different directions; combining without monitoring is real risk. Anyone running this stack should have baseline + monthly resting heart rate, blood pressure, and ideally HbA1c trend before deciding it's working. Active or recent cardiovascular disease, uncontrolled hypertension, history of stimulant abuse, pregnancy and breastfeeding: hard contraindications.
Where Panya stands
Tesofensine is documented at panya.health/peptide/tesofensine with the mechanism, Phase 3 data, side-effect profile, and the cross-border-prescribing reality. Panya does NOT yet route to vendors for tesofensine because (a) it's prescription-only where approved, (b) non-GLP-1 vendor scoring is gated on lawyer review. For users in countries where Tesomet is sold legally (Mexico, parts of LatAm), the compound page lists the registered route. For users elsewhere, the page documents what exists without endorsing import.
Read about this peptide
Related posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
Roughly 25 percent of weight lost on tirzepatide is lean mass unless you intervene. The protein target, training cadence, and supplement stack that preserves muscle during GLP-1 weight loss, per Attia...
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.